Adipokine profi le in patients with ischemic heart disease in stenting of the coronary arteries: contribution of changes in psychoemotional status

Objective: to investigate the adipokine profile’s changes, depending on the presence or absence the signs of psychoemotional disorders in the form of associated affective symptoms in patients with stable coronary heart disease (CHD) without diagnosed carbohydrate metabolism’s disorders undergoing routine percutaneous coronary intervention (PCI) with stenting, and also to assess their relationship with clinical outcomes within 1 year after hospitalization.

Materials and methods: the study included 20 male patients with stable angina pectoris of functional classes II – III, hospitalized for coronary stenting. The severity of affective symptoms were being assessed. The levels markers of adiponectin, leptin, resistin in the blood plasma were determined before PCI and on the 3rd day after the operation.

Results: patients with stable coronary artery disease had increase in resistin concentrations and a decrease in adiponectin levels compared with reference. The change of psychoemotional status was accompanied by an initially more expressed increase in the concentrations of plasma resistin. The resistin’s level has been signifi cantly increased on the third day after PCI in patients without depressive symptoms. The dynamics of depressive symptoms hasn’t observed during the year. Clinically unfavorable outcomes, including stent’s restenosis, re-hospitalization, and the increase in angina attacks, were recorded more oft en in patients with subclinical symptoms of depression that persisted throughout the observation period.

Conclusions: the factors that negatively aff ected the cardiac prognosis were the disorders of the psychoemotional status and adipokine’s changes, including аn increasе of resistin’s and a decrease of adiponectin’s levels.

1. Fozilov H.G., Alekyan B.G. Complications of percutaneous coronary interventions - classifi cation, predictors of development and types of complications. Th e bulletin NTsSSH of A.N. Bakulev of the Russian Academy of Medical Science. Cardiovascular diseases. 2010;11(5):9-15. (In Russ.) eLIBRARY ID: 15548087

2. Dubatova I.V., Lepyavka S.V., Safronenko A.V., Demidov I.A., Voyakina V.G. Comorbidity of anxiety-depressive disorders and somatic pathology. Head physician of the South of Russia. 2019;68(4):52-55. (In Russ.) eLIBRARY ID: 39207427

3. Hryhorczuk C, Sharma S, Fulton S. Metabolic disturbances connecting obesity and depression. Fronties in neuroscience. 2013;7:177. https://doi.org/10.3389/fnins.2013.00177

4. Woodward L, Akoumianakis I, Antoniades C. Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular diseasе. Br J Pharmacol. 2017;174(22):4007-4020. https://doi.org/10.1111/bph.13619

5. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J. Am. Med. Assoc. 2012;291(14):1730– 1737. https://doi.org/10.1001/jama.291.14.1730

6. Chiu TY, Chen CY, Chen SY, Soon CC, Chen JW. Indicators associated with coronary atherosclerosis in metabolic syndrome. Clin. Chim. Acta. 2012;413(1–2):226–231. https://doi.org/10.1016/j.cca.2011.09.033

7. Schaffl er A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an infl ammatory organ in human diseases. Endocr Rev. 2006;27(5):449–467. https://doi.org/10.1210/er.2005-0022.

8. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Infl ammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci. 2011;16:1663. https://doi.org/10.2741/3812

9. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165:622-632. https://doi.org/10.1111/j.1476-5381.2011.01369.x

10. Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J. Atherosclerosis. Thromb. 2011;18(2):108–114. https://doi.org/10.5551/jat.6023

11. Burnett MS, Devaney JM, Adenika RJ. Cross-Sectional Associations of Resistin, Coronary Heart Disease, and Insulin Resistance. J. Clin. Endocrinol. Metab. 2014;91(1):64-68. https://doi.org/10.1210/jc.2005-1653

12. Oganov R.G. High-quality clinical practice with the basics of evidence-based medicine. Textbook for the system of postgraduate and additional professional education of doctors. Moscow: Silicea-Polygraph; 2011. (In Russ.)

13. Neumann FJ, Sousa-UM, Ahlsson A, Alfonso F, Banning AP, et al. ESC/EACTS Guidelines on myocardial revascularization. Eur.Heart J. 2018;40(2):87-165. https://doi.org/10.1093/eurheartj/ehy394

14. Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for Depression in the General Population with the Center for Epidemiologic Studies Depression (CES-D): A Systematic Review with Meta-Analysis. PLoS One. 2016;11(5):15-20. https://doi.org/10.1371/journal.pone.0155431

15. Chrysohoou C, Kollia N, Tousoulis D. The link between depression and atherosclerosis through the pathways of infl ammation and endothelium dysfunction. Maturitas. 2018;109:1–5. https://doi.org/10.1016/j.maturitas.2017.12.001

16. Teplyakov A.T., Akhmedov S.D., Suslova T.Y., Andriyanova А.V., Kuznetsova A.V., et al. Infl uence of resistin on the course of ischemic heart disease in patients with type 2 diabetes mellitus. Bulletin of Siberian Medicine. 2015;14(5):73-82. (In Russ.) https://doi.org/10.20538/1682-0363-2015-5-73-82

17. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial eff ects of adiponectin. Nat. Clin. Pract. Cardiovascular. Med. 2009;6(1):27–35. https://doi.org/10.1038/ncpcardio1398

18. Nishimura M, Hashimoto T, Kobayashi H, Yamazaki S, Okino K, et al. Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol. Dial. Transplant. 2006;21(6)1640-1647. https://doi.org/10.1093/ndt/gfk088

19. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study. Circulation. 2018;104(25):3052–6.https://doi.org/10.1161/hc5001.101061

20. Shioji K., Moriwaki S, Takeuchi Y, Uegaito T, Mutsuo S, Matsuda M. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergopercutaneous coronary intervention. Circ. J. 2014; 71(5):675-680. https://doi.org/10.1253/circj.71.675

21. Pertseva N.O., Khrustalova L.O. Assessment of the dynamics of depressive disorders in patients with coronary artery disease depending on the method of restoring the blood supply to the heart. Clinical medicine. 2017;18(1):26-30 (In Russ.) https://doi.org/10.26641/2307-0404.2018.2.133699

22. Dijk MR, Utens EM, Dulfer K, Al-Qezweny MN, van Geuns, et al. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of followup. Eur. J. Prev. Cardiol. 2016;23(5):552–558. https://doi.org/10.1177/2047487315571889

23. Silha JV, Krsek M, Skrha IV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects. Correlation with insulin resistance. Eur. I Endocrinol. 2003;149(4):331–335. https://doi.org/10.1530/eje.0.1490331

24. De Jager TA, Dulfer K, Radhoe S, Bergmann MJ, Daemen J, et al., Predictive value of depression and anxiety for longterm mortality: diff erences in outcome between acute coronary syndrome and stable angina pectoris. Int. J. Cardiol. 2018;250:43–48. https://doi.org/10.1016/j.ijcard.2017.10.005